Market Overview: The global market for Hepatitis A vaccines displayed significant strength in 2020 and is poised for steady revenue growth throughout the forecast period. Key drivers of this growth include the increasing prevalence of chronic diseases, government initiatives aimed at promoting health awareness, and the vaccine’s high effectiveness in disease treatment.
Get a sample copy of the Hepatitis A Vaccine Market report: https://www.reportsanddata.com/download-free-sample/4572
Strategies and Objectives of Major Companies: GlaxoSmithKline plc is a pharmaceutical company specializing in pharmaceutical medications, vaccines, and consumer healthcare products. The company’s core segments are Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team. It produces a range of vaccines, including those for Hepatitis A and B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis.
Hepatitis is a liver inflammation caused by either infectious or non-infectious factors. The Hepatitis A vaccine is a preventive measure with an efficacy rate of around 95% and a protection duration of at least twenty years. It is administered through injection and was first approved in Europe in 1991 and in the United States in 1995. The World Health Organization recognizes it as an essential medicine and recommends universal vaccination, as natural immunity typically develops during childhood.
The Centers for Disease Control and Prevention (CDC) recommends vaccination for the following groups:
- All children aged 12 to 23 months.
- Children and adolescents aged 2 to 18 who haven’t been vaccinated.
- Individuals at risk due to their occupation.
- Those in close contact with international adoptees.
- HIV-positive individuals.
- Patients with chronic liver disease.
Major Factors Driving Growth of the Global Hepatitis A Vaccine Market:
- High disease prevalence: Increasing disease prevalence enhances health awareness, contributing positively to market revenue growth.
- Government efforts: Supportive government vaccination initiatives, including free or reduced-cost vaccines, are expected to boost demand for Hepatitis A vaccines. Governments also run public awareness campaigns and immunization plans against Hepatitis A.
Factors Restraining Growth of the Global Hepatitis A Vaccine Market:
- High development costs: The development of vaccines is a costly and rigorous process that involves extensive research, experimentation, certification, government approvals, and compliance with regulations.
- Stringent regulations: Vaccine production necessitates substantial research, ongoing development, and adherence to government requirements and regulations, which can impede market growth.
Opportunities for Players in the Global Hepatitis A Vaccine Market:
- Increased health awareness: A growing focus on health and medical awareness creates business opportunities for both established and new market players. Collaboration between governments and private players in vaccination campaigns further supports market expansion.
Global Hepatitis A Vaccine Market Revenue by Product Type Segment: The inactivated vaccine segment is expected to dominate revenue generation during the forecast period. Inactivated vaccines are known for their safety and effectiveness, with a single dose often being sufficient for stable patients.
Global Hepatitis A Vaccine Market Led by Industry Type Segment: Government institutions are anticipated to lead in revenue generation over the forecast period, as public healthcare facilities play a critical role in Hepatitis A diagnosis and vaccination. Government vaccination campaigns are also expected to drive segment growth.
Asia Pacific Leads in Global Hepatitis A Vaccine Market Revenue Share: Asia Pacific held the largest market share in 2020, driven by a rising pediatric population and growing awareness of vaccination benefits. Government-led vaccination initiatives in emerging economies like India and China contribute to market growth in the region.
North America Leads in Revenue CAGR: North America is expected to experience the highest revenue CAGR due to advancements in the healthcare sector, increased prevalence of chronic diseases, higher healthcare spending, and the presence of key market players.
HAVRIX, a Hepatitis A virus vaccine by GlaxoSmithKline, is approved for individuals aged at least 12 months and is administered at least two weeks before potential exposure to HAV.
What Our Report Provides and Why Our Offering Is Superior: The report offers historical data and forecasts, providing insights into revenue growth at global, regional, and country levels. It covers industry trends, consumption patterns, and analysis for each region, major country, and segment from 2018 to 2028. The report includes a detailed view of the global market, competitive landscape, company financials, and impact analysis.
Detailed Segmentation in Our Report: The global Hepatitis A vaccine market is segmented based on product type, industry type, channel type, and region:
Product Type Outlook (Revenue, USD Billion; 2018-2028)
- Inactivated vaccine
- Live attenuated vaccine
Industry Type Outlook (Revenue, USD Billion; 2018-2028)
- Government Institution
- Private Sector
Channel Type Outlook (Revenue, USD Billion; 2018-2028)
- Direct Sales
- Distributor
Region Outlook (Revenue, USD Billion; 2018-2028)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Explore Trending Reports:
Autoimmune Disease Diagnosis Market-https://www.globenewswire.com/news-release/2020/08/20/2081722/0/en/Autoimmune-Disease-Diagnosis-Market-To-Reach-USD-7-37-Billion-By-2027-Reports-and-Data.html
Protein Expression Market-https://www.globenewswire.com/en/news-release/2021/04/19/2212656/0/en/Protein-Expression-Market-Size-to-Reach-USD-6-07-Billion-in-2028-CAGR-of-13-5-Reports-And-Data.html
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/4572
Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release